United Therapeutics Q2 Profit Rises - Quick Facts

(RTTNews) - Drug manufacturer United Therapeutics Corp. (UTHR), Thursday reported an increase in net income for the second quarter, mirroring higher revenues.

Net income for the quarter was $79.8 million or $1.52 per share, compared with $72.3 million or $1.34 per share, last year. Earnings before non-cash charges for the three-month period were $163.7 million or $3.11 per share.

On average, thirteen analysts polled by Thomson Reuters expected earnings per share of $1.47 for the quarter. Analysts' estimates typically exclude one-time items.

Total revenues for the tri-monthly period increased to $280.6 million, up from $225.6 million reported during the same quarter last year. Street's revenue estimate was $250.17 million.

Looking forward, the drug maker reaffirmed its full-year revenue guidance for three commercial products, Remodulin, Tyvaso and Adcirca, as the company expects related revenues to fall within a range of 5 percent above or below $1 billion for the year.